Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
To Evaluate the Effects of Ceftazidime-Avibactam and Best Available Therapy in patients with
complicated urinary tract infections and complicated intra-abdominal infections.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca Pfizer
Collaborator:
Forest Laboratories
Treatments:
Anti-Infective Agents Avibactam Avibactam, ceftazidime drug combination Ceftazidime Metronidazole